^
Association details:
| Biomarker: | POLE V411L |
|---|---|
| Cancer: | Endometrial Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
526O - High activity of nivolumab in patients with pathogenic exonucleasic domain POLE (edPOLE) mutated Mismatch Repair proficient (MMRp) advanced tumours
Published date:
09/20/2020
Excerpt:
Responses were observed in MMRp colorectal and endometrial cancers with P286R and V411L mutations….Nivolumab activity appears promising in edPOLE mutated MMRp advanced cancer pts...
Trial ID:
